Furosoral contains furosemide and is indicated for the treatment of hydrothorax, hydropericardium, ascites and oedema, particularly in animals where these conditions are associated with cardiac insufficiency and renal dysfunction.
Furosoral replaces Dechra’s previous diuretic treatment, Frusedale.
It is available in both 10 mg and 40 mg double-divisable tablets.
The recommended daily starting dose for cats and dogs is 2.5 mg per kg of body weight.
Dechra says careful weighing is essential to ensure accurate dosing, but that the dosage can be doubled initially for severe or particularly resistant cases and adjusted to the lowest clinically effective dose for maintenance therapy if required.
Dechra companion animal brand manager, Charlotte Hill, said: “Furosoral offers a flexible treatment solution where dosage can be adjusted, depending on the needs of the patient and the underlying causes, to give vets more options for treating cats and dogs with fluid retention.
“To ensure it is as appealing to pet owners as it is to veterinary professionals, Furosoral is available in our innovative Smart Tab format, giving owners confidence that they are giving their dog or cat the right dosage and aiding compliance, leading to better outcomes for the animal.”
Furosoral 10 mg and 40 mg tablets are available in blister packs of 100 tablets for quick and easy dispensing. Divided tablets can be stored in the blister pack for up to three days, ensuring no waste.
https://www.dechra.co.uk/products/dog/prescription#/search=furosoral/.
Idexx Laboratories has launched a total T4 dry-slide test, giving veterinary surgeons real-time access to additional chemistry information.
The new test is compatible with all the company’s in-clinic laboratory analysers.
Simon Wootton, UK Marketing Manager from Idexx says that it is important for vets to be able to update a patient’s chemistry during a visit: “Conditions like hyper- or hypothyroidism require intervention and careful long-term monitoring. It is also important to assess the possible effects on other relevant medical parameters. This is why vets often want to update a patient’s chemistry data during the clinic visit. To accommodate this need, accurate and dependable chemistry, electrolyte and T4 test results can now be delivered in as little as 15 minutes.
“By adding thyroid screening to diagnostic protocols – which may already include fructosamine, phenobarbital, and urine P:C testing – practices can now get comprehensive chemistry, electrolyte and T4 measurements from a single sample, in a single run. This will let vets detect abnormalities sooner and respond more effectively.”
For more information, visit: https://www.idexx.com
Redonyl Ultra contains essential fatty acids, Palmitoylethanolamide (PEA) and Biotin.
PEA is a naturally-occurring bio modulator which Dechra says has scientifically proven activity against the mechanisms that contribute to inflammation and pain, while Biotin is important for synthesis of fatty acids and support of optimal skin condition.
Dechra Brand Manager Claire Morgan said: "Redonyl Ultra is a great addition to Dechra’s extensive Dermatology range that allows an holistic approach to treatment, control and maintenance of dermatological conditions.
"Allergic skin conditions are among the most common causes of skin and ear disease in cats and dogs, and it is estimated that up to 15 per cent of dogs are affected by atopy. In situations where an allergen cannot be avoided, multi-modal therapy is useful to control the clinical signs."
Redonyl Ultra comes in a convenient bottle size of 60 skittle capsules, in two strengths for different sized animals. The capsules can be opened and given with food or ingested directly, or swallowed whole for flexible administration.
For more information, visit http://bit.ly/2iNa2Ik
Lecture topics will include interesting cases, the importance of systematic abdominal technique, the challenge of becoming ultrasound competent within a primary referral setting, basic anaesthetic nerve blocks, using ultrasound for appropriate medical management, how CASE can support competency based veterinary ultrasound training and more.
The session will end with a debate on whether it is time for a formal / stand alone Veterinary Ultrasound training programme and who should accredit such courses.
Speakers include Natasha Dickinson from Cave Veterinary Specialists, Niamh Casey from Village Vets, Miguel Martinez from Northwest Veterinary Specialists, Will Humphreys from the University of Liverpool and Nuala Summerfield from Virtual Veterinary Specialists.
The day costs £75 (sounds like a steal, if you ask me), and you can register here: https://www.bmus.org/meeting-booking/ultrasound-2019/
The study analysed information from a random sample of 29,865 dogs that died over a one-year period, taken from a study population of 905,544 dogs from 626 clinics in the VetCompass database.
From the sample, 26,676 (91.5%) of deaths recorded in practice involved euthanasia and 2,487 (8.5%) of deaths were unassisted. However, it is unknown how many dogs die unassisted and unreported to a practice.
Perhaps unsurprisingly, the findings indicated that certain types of diseases and conditions were more likely to lead to death by euthanasia than unassisted death.
by contrast,
Larger bodyweights, increasing age and certain breeds of dog were also additional risk factors for euthanasia. Rottweilers were more likely to die by euthanasia compared to Labrador Retrievers as the standard baseline breed. In contrast, breeds such as Bulldogs, Pugs and West Highland White Terriers were more likely to have unassisted deaths, and these deaths were more likely caused by traumatic injury, foreign body and heart disease.
Additional findings from the study included:
Camilla Pegram, VetCompass Epidemiologist at the RVC, and author of the paper, said: “End-of-life discussions between veterinarians and owners can be particularly difficult for both parties. This study provides benchmark data for the relative proportion of deaths that involve euthanasia and for the relative impact from demographics and disorders on euthanasia decision-making. Owners and veterinary professionals may find it easier to discuss end-of-life options, to reach a final decision and be comfortable with these decisions based on a feeling of broader support from the reported actions of others in similar situations.”
Dr Dan O’Neill, Senior Lecturer, Companion Animal Epidemiology, at the RVC, and co-author of the paper, said: "The decision for many animal owners to put a beloved dog to sleep is often the hardest decision of their life. The moment of euthanasia often lives with owners forever. Hopefully, the information from this study can at least help some owners come to terms with the responsibility of helping their dog go with dignity. Understanding that over 90% of other owners also opted for euthanasia may help anyone struggling to make this final and hardest decision.”
Dr Carol Gray, Research Associate at the University of Liverpool and co-author of the paper, said: "Decision-making around euthanasia is shared between veterinarian and owner, although it is the owner who must give consent for euthanasia. Providing this final authorisation is potentially a burden for owners. This paper will help to ease that burden by allowing veterinarians to provide reassurance that they are not the only dog owners to make a decision for euthanasia in similar circumstances.”
Reference
Pegram, C., Gray, C., Packer, R.M.A. et al. Proportion and risk factors for death by euthanasia in dogs in the UK. Sci Rep 11, 9145 (2021). https://doi.org/10.1038/s41598-021-88342-0
Zoetis has launched a 4ml vial of the antibiotic, Convenia.
Zoetis says Convenia gives veterinary surgeons control by providing an assured injectable treatment course, relieving clients of the burden of daily dosing. This avoids missed or mistimed doses, lost tablets, or courses stopped too soon, thereby eliminating a major reason for treatment failure, non-compliance. Poor compliance is also a significant factor in the development of antimicrobial resistance.
Convenia is licensed for skin, soft tissue and urinary tract infections in dogs and cats, as well as severe gingivitis/periodontitis in dogs (as an adjunct to mechanical or surgical periodontal therapy). A 4ml vial can treat up to 40kg of bodyweight, making it appropriate for treating cats and smaller dogs.
Zoetis says that the launch of the new vial demonstrates its commitment to the 'Respect Antibiotics' campaign launched last year. The Respect Antibiotics campaign encourages careful and informed selection of appropriate antibiotic therapies for the treatment of dogs and cats.
Product Manager, Andrew Page, said; "We are committed to encouraging responsible antibiotic usage, and reducing the incidence of antibiotic resistance. Non-compliance plays a key role in the development of antibiotic resistance and we hope that by making Convenia more accessible through the introduction of a 4ml vial we can help alleviate compliance issues."
For further details about Convenia please contact your Zoetis Account Manager.
Zesti comprises three ranges:
The Spirit range is a more standard looking scrub, manufactured from Alsi-Flex. The ‘Mode’ range looks a little more figure hugging, with an exclusive colour palette, and the Power range has a more sporting look.
Greg Houlston, General Manager, said: “Our healthcare workers need clothing that is practical and comfortable above anything else, yet our market research showed us that when it comes to scrubs with stretch, choice is limited in the UK compared with other markets such as the US.
“Veterinarians in particular need workwear that is especially hard wearing as the nature of their work means their clothing can be especially susceptible to rips, tears and soiling.
“We set out to create a brand that answered the need for more flexibility while challenging the perception that workwear should be dull and boring, and Zesti was born – a vibrant and contemporary range of garments, sustainably designed, to inspire confidence and positivity.”
Sara Catanzaro, Design Manager, added: “Our tailored garments offer exceptional attention to detail while being strong, hard wearing and resilient.
"They can be laundered domestically or industrially up to 60 degrees which is ideal for infection control.
"We’re already witnessing considerable demand as we believe we’ve hit the perfect balance between function and fashion.”
For more information, visit www.zesti.co.uk
Squamous cell carcinoma affects horses’ genitalia, eyes, or skin around the eyes. The tumours typically have a guarded to poor prognosis, and the therapeutic approaches available have variable success rates. Euthanasia on welfare grounds is necessary in a significant number of cases.
Before this new research was published, pathologists and researchers Dr Alejandro Suárez-Bonnet and Professor Simon Priestnall, both from the RVC, had already undertaken research which showed that equine squamous cell carcinoma affecting the penis frequently acquires the ability to degrade the extracellular matrix and become much more biologically aggressive2. This is known as ‘epithelial to mesenchymal transition’.
This new study, recently published in Scientific Reports, is the product of a multi-institutional effort, which used both “classical” anatomic histopathology assessment and artificial intelligence to demonstrate a correlation between chronic inflammation, equine papillomavirus infection and progression of equine penile squamous cell carcinoma.
Several additional cancer-related signalling molecules, which are important in researchers’ understanding of human penile cancer, were also studied and the results obtained will lead to a much better understanding and treatment of the cancer.
Simon Priestnall, Professor of Veterinary Anatomic Pathology at the Royal Veterinary College, said: “Equine squamous cell carcinoma is the second most common type of cancer in horses, with a variable prognosis, so we are delighted to have made this breakthrough that provides a greater understanding and can lead to more effective treatments for horses and their owners.
"The RVC has always recognised the value of collaboration, and Alejandro and I enjoyed working alongside the teams at KCL, the University of Edinburgh and UCL. This project shows what can be achieved when different organisations work together with a common aim and we hope the similarities between the tumour in horses and people can offer a true One Health benefit."
Dr Alejandro Suárez-Bonnet, Lecturer in Comparative Pathology at the Royal Veterinary College, said: "I am so pleased with the results of this study, which will hopefully pave the way for improved prognosis of horses diagnosed with equine squamous cell carcinoma.
"Our work is not over, however. Thanks to the help of a grant from the Horse Race Betting Levy, Simon and I are leading a Master’s degree project investigating equine penile, ocular and vulvar squamous cell carcinomas from a broader perspective.
"Our hope is to identify if variability exists between equine papillomavirus infectious status, morphological and microscopic difference, and cancer progression, with the aim of identifying potential therapeutic targets as well as diagnostic markers with prognostic implications for maximum benefit to the British equine population.”
References
The app, which works on tablets and smartphones, allows vets to e-mail audit results directly to clients following an interactive calf health assessment at the farm.
MSD Animal Health’s youngstock marketing manager Robert Simpson said: “Our new app allows both parties to explore, record and score calf health performance across five core areas to identify the strengths and weaknesses of any rearing unit’s environment and processes.
“Working through a series of 10 questions within each core area – designed to tease out where a rearing unit is in terms of accepted best management practice – allows vet and farmer to quickly pinpoint any areas needing attention.
"What’s more, repeating the checklist every six or 12 months is a great way to keep things on track, allowing both parties to monitor progress against agreed targets”.
For more information about the app, contact your MSD account manager.
The tips, put together by Tessa Plagis (communication advisor at St. Anna Advies), Alan Robinson (director of VetDynamics) and Rebecca Robinson (coach at VetDynamics and senior clinician in veterinary anaesthesia at the AHT), are being shared to set the scene for Congress 2023, where international experts will be exploring how time management at organisational, systems, teams and an individual levels can lead to drastic improvements in performance, job satisfaction and wellbeing.
The Association points to the demands on the profession caused by the fact that veterinary professionals have been saying 'yes' to everything for years: yes to more clients, more patients and more overtime.
This, says BSAVA, is taking its toll: experienced practitioners and recent graduates are leaving the profession, and many more are suffering mental and physical health issues associated with sustained high stress.
Tessa Plagis, communication advisor at St. Anna Advies, said: “We are at a tipping point and can’t keep doing what we’ve always done. If we want sustainable veterinary businesses going forward we need to change the structure of how we work.”
Tessa says the issues are both organisational and individual: “Many veterinary professionals struggle to give boundaries.
"We are people pleasers and tend to say ‘yes’, even if that means compromising other important aspects of lives, such as family.
"This set against a background of too few vets, which means that there’s nobody to help us out when there’s too much to-do.”
To find out more about time management, book your ticket for BSAVA Congress at: https://www.bsavaevents.com/bsavacongress2023/en/page/home, and in the meantime, here are Tessa, Alan and Rebecca's time management tips.
Tessa's tips
Alan's tips
Rebecca's tips
The programme, which will look at the achievements and contributions of people of African and Afro-Caribbean descent, will see Dr Greene being interviewed by presenter Alex Beresford alongside a number of other prominent black Britons including athlete and broadcaster Colin Jackson, publisher and author Margaret Busby, Mayor of Bristol Marvin Rees, and nurse and academic Dame Elizabeth Anionwu.
Mandisa said: “I am immensely honoured to be the first Black President of the RCVS and to use this opportunity to speak to the black community, and indeed all communities, about my love of veterinary science and the importance of the work we do in safeguarding animal health and welfare and wider public health.
"I am a great believer in the phrase ‘if you see it, you can be it’ and I hope that my various talks this month and, particularly the upcoming ITV documentary, will help people recognise that veterinary professionals can come from a diverse range of backgrounds and that, provided they have the drive and the ambition, there should be no barriers to them meeting their dreams."
FirstVet says the funding will enable it to expand its service globally, including the United States, Germany, and France. It will also allow it to continue developing its product and introduce new features to improve the experience for pet owners and vets, such as new automation tools and integration with clinics' existing systems.
The latest round of financing takes FirstVet’s total funding to-date to €24.5M.
Founded in 2016 in Sweden, FirstVet currently has a presence in five markets: the United Kingdom, Norway, Denmark, Finland, and its native Sweden. The company says it has over 200,000 registered users and has provided consultations for over 150,000 pets since launch.
Currently, FirstVet consultations are offered free to millions of owners through partnerships with 20 insurance companies across all markets, including Bought By Many in the UK.
Co-founder David Prien said: "FirstVet is the first truly neutral stakeholder in the world to coordinate pet care. In what is a highly privatised industry, our reliable service provides value to the entire sector, and we are growing at an incredible rate."
Petplan has announced the results of a survey which shows that with less than a week to go before microchipping becomes compulsory in England, Scotland and Wales, there is still confusion about the law amongst pet owners.
In the survey of 2,000 British dog owners, 25% had not heard of the new law and 40% didn't know that it also requires owners to keep their microchip details up to date.
40% of respondents said they'd be happy to pay over £500 as a reward if their dog went missing. Despite this, 40% of those who were aware of the new law but had yet to chip their dogs admitted they had not done so because of reservations about the cost of the procedure.
The survey also highlighted the fact that even the most careful of owners lose their dogs. Nearly 40% of losses reported in the survey happened when the owner was taking their pet on a daily walk and 47.1% of respondents reported having a dog escape from an apparently secure garden.
The survey also found that a third of lost dogs came to harm while missing, most of which (84.8%) needed veterinary care.
According to Petplan, despite more than half of dog owners citing expensive veterinary bills as one of their biggest concerns around dog ownership, over 45% of respondents reported not having their dogs insured.
Petplan has published information for pet owners about the new microchip law here: petplan.co.uk/microchip-dog-law-info.
To use the service, you order recycling boxes to suite your needs, and then place them where it will be most convenient for staff to throw the rubbish in.
Once full, you send the box back to TerraCycle via UPS.
It is then saved from incineration or landfills and recycled by TerraCycle.
Once collected, products and packaging are sorted and separated by material composition.
The separated items are then cleaned, shredded, and made into new recycled products such as outdoor furniture and decking, playgrounds, benches, or watering cans.
Hannah James, Head of Environment, Social & Governance at VetPartners said: “We started using the Zero Waste Boxes at our practices during the pandemic to recycle the large volumes of PPE being used, and they were instantly popular with practice teams.
"We’re now recycling plastic packaging, pet food packaging and medicine blister packs through TerraCycle as well, and since 2020 we’ve saved over 14 tonnes of waste from landfill and incineration.
"The Zero Waste Boxes are an important feature of our sustainability strategy, providing a solution for much of the waste generated by veterinary practice that isn’t hazardous and yet isn’t widely accepted for recycling.”
www.vetcycle.co.uk
The most recent case of rabies in a bat in Great Britain was in July 2020 in Wimbourne, Dorset and there were four cases in 2019.
Like many wild animals, bats can carry a number of different pathogens, including European Bat Lyssaviruses (EBLVs) 1 and 2 – also referred to as bat rabies. The rabies virus is present in the saliva of infected bats and is usually spread to humans or other mammals by the bite of an infected bat. The virus may also enter the body via open wounds or mucous membranes.
The BSAVA says that whilst the risk of transmission to humans is considered low, those handling bats may be at an increased risk of contracting the disease and those who regularly handle bats should be vaccinated against rabies.
Those who are not vaccinated against the disease should assume that all bats are possible carriers of rabies. Individuals handling bats should wear gloves of a suitable thickness for the species of bat they are handling to avoid being bitten or scratched. Further information on how to safely contain and handle a bat can be found on the Bat Conservation Trust website.
In the event that an individual is bitten or scratched by a bat or exposed to bat saliva or nervous tissue in any other way, they should seek immediate medical advice. The contact area should be washed with soap and water, and any wounds must be disinfected. Further information can be found on the APHA, PHE and NHS websites.
In 2008, a case involving an injured bat carrying EBLV type 2 was treated by a vet and her staff, who were unaware of the potential of rabies risk from bats. The bat handlers had previously been vaccinated as recommended by the Department of Health but despite sustaining a needlestick injury during surgery, the vet and her staff had neither sought nor received post-exposure prophylaxis.1
Professor Ian Ramsey, president of the BSAVA, said: “Although this case was 12 years ago it is a pertinent reminder of why we need to be well-prepared when handling bats. Whilst the risk of human rabies infection from bats is low, the publication of the new statistics show that EBLVs are circulating in a small number of wild bats. Injured bats are often presented to small animal vets, so we have taken this opportunity to remind our members and others of the potential risks of rabies transmission, and how to mitigate against these.
"For more advice on the handling and treatment of wildlife casualties including bats, we advise vets to consult a reference book such as the BSAVA Manual of Wildlife Casualties."
Research amongst veterinary surgeons by Janssen Animal Health, maker of Cavalesse oral and Cavalesse topical, has revealed that owners could be doing more harm than good when it comes to managing sweet itch in their horses.
92% of vets questioned are aware that people follow old wives' tales by administering lotions and potions such as garlic and olive oil to ward off flies during the summer sweet itch season, when garlic actually has the opposite effect of attracting them.
According to Janssen, it is thought that only a quarter of horse owners are aware that it is important to carry out preventative measures before the start of the midge season to help alleviate sweet itch. 14% of people are thought to go to their vet for advice on sweet itch, while 30% seek help from their country store or tack shop, 27% search for information on websites and 26% ask other horse owners for guidance. This is despite the fact that 92% of those questioned believe that sweet itch would clear up quicker if people sought advice from their veterinary surgeon.
Nicki Glen, marketing manager at Janssen Animal Health said: "Sweet itch can be an incredibly difficult and frustrating condition to manage, however horse owners do not tend to seek advice from their vets. It is therefore important to educate horse owners while you are on yard visits with pro-active advice on the condition for the long-term health and welfare of horses."
Cavalesse is a natural food supplement containing a specialised formulation of water-soluble vitamins and minerals, including nicotinamide. Once a month the contents of each sachet are dissolved in water to form an oral solution, which can be administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat such as a sugar lump. Janssen says the supplement helps horses maintain a healthy skin and promotes normal immune function in horses prone to summer allergies.
Cavalesse Topical is a skincare gel that can be used in combination with the Cavalesse solution. The gel can be applied to the skin to help support natural immunity from the outside, whilst the oral solution works in partnership from the inside.
For further information on Cavalesse and Cavalesse Topical please contact your Janssen Animal Health account manager or phone 01494 567555.
The current strain of bluetongue emerged in the Netherlands in 2023 and spread rapidly, infecting over 5,000 livestock farms.
Infection of livestock with this serotype of the virus can result in severe clinical signs and high mortality rates1, significantly impacting animal health, and farming communities.
Bultavo 3 is an inactivated injectable vaccine indicated for the active immunisation against BTV-3.
Boehringer says that in sheep, Bultavo 3 has been shown to significantly reduce viraemia and prevent mortality and clinical signs associated with BTV-3 infection.
Onset of immunity occurs three weeks after administration of a single 1ml subcutaneous dose in sheep.
In cattle, two 1ml intramuscular doses are required, at a three-week interval.
Findlay MacBean, Head of Livestock, UK and Ireland at Boehringer Ingelheim, said: “It’s great news that we can support farmers and authorities in their fight against bluetongue with our new BTV-3 vaccine, Bultavo 3.
"As we have seen across Europe, and now in the UK, BTV can spread rapidly and causes considerable stress to farmers because of the significant financial impact on those affected.
The availability of Bultavo 3 means future BTV-3 outbreaks can be suppressed, helping farmers protect not only their herds, but also their livelihoods.” Oli Maxwell, BVSc BSc(Hons) MVM DipECBHM, RCVS Recognised Specialist in Cattle Health and Production and Clinical Director of Green Counties Vets said: “Farmers are justifiably concerned about BTV-3 and its incursion into the UK again this year.
"Reports from colleagues on the continent regarding the severity of clinical signs, especially in sheep are worrying.
"We have seen a huge increase in clients asking about the disease, progress on a vaccine and what this may mean for animal movements at a critical time of year.
"The availability of a safe and effective vaccine as a critical tool against a disease that we can’t reasonably prevent with biosecurity measures will be a welcome development for many.”
To manage supply and demand, use of the product will initially be subject to geographical restriction with vaccination permitted in high-risk English counties: Norfolk, Suffolk, Essex, Kent and East Sussex.
Reference:
Bayer Animal Health has taken over the marketing and sales of the antibiotic Nisamox (tablets containing Amoxicillin and Clavulanic Acid), from Fort Dodge Animal Health.
Under the new arrangement, the design of Nisamox tablet packaging will change to reflect the change of ownership, however, Bayer says the quality of the tablets and the competitive pricing remain unchanged.
Nisamox tablets are licensed for use in cats and dogs to treat infections of the skin, urinary tract, and respiratory tract caused by susceptible Staphylococci, and also to treat enteritis and urinary tract infections caused by susceptible E.coli.
Nisamox tablets will continue to be available in three strengths: 50mg, 250mg, and 500mg. For information on Nisamox tablets, contact your Bayer territory manager.
Historically, diagnosis has been achieved with multiple blood tests. However, this process can be time-consuming, expensive and in some cases does not provide accurate results.
In an attempt to address these diagnostic challenges, the researchers, with funding from Dechra, assessed anonymised data from 939 dogs which had been tested for Cushing’s syndrome from the VetCompass population of 905,554 dogs and 886 veterinary practices across the UK1.
Using structured clinical data to look at the dogs’ demographics, clinical signs at presentation and laboratory results, machine-learning algorithms were applied to predict a future diagnosis of Cushing’s syndrome. Dogs suspected of having Cushing’s syndrome were included in the analysis and classified based on their final reported diagnosis within their clinical records.
The researchers say that the findings indicate that machine-learning aided diagnosis could predict the diagnosis of a practising veterinary surgeon and that using machine-learning methods in clinical practice could contribute to improved diagnosis of Cushing’s syndrome in dogs.
Additionally, further development of these algorithms could lead to earlier, more reliable and cost-effective diagnoses and therefore, better clinical care for dogs with Cushing’s syndrome. This could also create opportunities for this technology to be applied to other clinical problems.
Imogen Schofield, lead author and PhD student at the RVC, said: “Machine-learning algorithms, like those used in this study, are already widely integrated in our day-to-day lives to help make certain decisions, such as Google or Netflix recommendations. Now this technology can be harnessed to help improve diagnostics in veterinary practice.
"By embracing the use of machine-learning methods, we are a step closer to providing vets in primary-care practice with an easy to use, low cost and accurate test that can support the often frustrating process of diagnosing Cushing’s syndrome in dogs."
Greg Williams, Senior Business Manager at Dechra Ltd. and Industrial Supervisor of the PhD studentship, said: “By funding Imogen's PhD and working with the RVC we have been able to develop validated clinical scoring and quality-of-life assessments to help vets deliver effective control and management of Cushing's syndrome in dogs.
NOAH's third Brexit Barometer found that where in the last report, 17% of its members reported feeling 'very' or 'somewhat pessimistic', that figure has now risen to 32%.
Meanwhile, the National Audit Office has revealed in its 'Progress in Implementing EU Exit' report that Defra has been prevented from consulting with the veterinary market by DExEU.
The report states that Defra is one of the government departments most affected by EU Exit and looks in detail at four of Defra’s main workstreams, including ‘import of animals and animal products’ and ‘exports of animals and animal products’.
In an accompanying press release, the National Audit Office notes that in a no-deal scenario there will be a significant increase in certificates needing to be processed by veterinary surgeons. It says: "Without enough vets, consignments of food could be delayed at the border or prevented from leaving the UK. Defra intended to start engaging with the veterinary industry in April 2018, but has not been permitted to do so and now plans to launch an emergency recruitment campaign in October to at least meet minimum levels of vets required. It plans to meet any remaining gaps through the use of non-veterinarians to check records and processes that do not require veterinary judgement."
The BVA says it has previously outlined concerns about the potential for diluting veterinary certification, and is calling on the Government to fully engage with the veterinary profession before making any changes that could impact the UK’s ability to trade animal products safely and in line with high animal welfare standards.
The RCVS has also weighed in. Amanda Boag, RCVS President, said: "We are glad to see the National Audit Office report recognises that a ‘no deal’ Brexit scenario would be likely to reduce the supply of EU veterinary surgeons to the UK and cause uncertainty regarding the status of those EU veterinary surgeons who are currently living and working in the UK and that this would have a particularly serious impact on necessary veterinary work in public health and certification.
"We continue to engage with Defra and, like the BVA, we want to emphasise the essential need for Government to consult with the profession to ensure their plans meet requirements, including maintenance of the high veterinary standards for which the UK is known. We also want to highlight the importance and value of the veterinary profession in other areas of society including caring for pets, horses and farm animals as well as research, education and industry, and emphasise the impact of workforce shortages on all sectors."
iRecall Consent Management falls into two parts: an initial three staged campaign to gain clients' consent before the 25th May deadline, then ongoing maintenance of the database, managing existing clients' communication preferences and gaining consent for new clients.
Thereafter, iRecall will cross reference consent and communication preferences for any iRecall-powered outbound marketing communication for a practice.
Practice-branded client consent requests are created in real time using live practice data and are personalised for each individual client and their pets.
Consent Management uses the company's SMARTdelivery technology to maximise response rates: first selecting the best delivery method (SMS, email or letter) for each client, based on current information in the practice management system. If a message fails to send because of an invalid number or email address, Consent Management automatically selects the next delivery method.
iRecall says Consent Management already interfaces with the six leading practice management systems, and can interface with any system on request.
Jamie Crittall, Director of Virtual Recall and himself a practice owner said: "Practices need to stop thinking that GDPR is a burden but see it as opportunity to forge stronger relationships with their clients and helping them to keep their pets healthy. Practices who treat their clients’ personal data with the same care that they show their pets will be rewarded with greater trust and loyalty, ensuring the future success of their business. Furthermore, it’s the perfect opportunity for practices to re-engage with previously lapsed clients to make them active and loyal once more - a massive value add."
For more information, visit: http://www.virtualrecall.com/
Virbac points to how the pandemic has caused a fundamental shift in consumer shopping habits, with e-commerce accounting for more than 30% of retail sales in the UK in 2020 for the first time1.
Alongside the increase in online sales has come an expectation by consumers that all companies should provide a reliable digital service, with 70% saying that they will continue to buy essential goods online post-pandemic2.
At the same time, sales of pet food in the majority of veterinary practices have been hit by the need for social distancing.
Through the new model, when pet owners buy Virbac's low-carb, high protein Veterinary HPM dog and cat food from the company's new web store for home delivery, a commission is paid to the practice.
Remi Mandray, Product Manager at Virbac said: "It’s a win-win for our practices and their clients, who can take advantage of this convenient option to have their pet food delivered to their home, whilst providing the practice with a protected and rewarding business model".
For more information, contact your Virbac Territory Manager.
Apoquel chewable tablets were approved by the Veterinary Medicines Directorate (VMD) in November 2021.
Apoquel Chewable contains the same active ingredient, at the same dosing regime, for the same indications as original Apoquel, but in a palatable formulation which, in a field-study of client-owned dogs, was found to have a 91.6% acceptance rate.1
Dr Carly Mason, President of the British Veterinary Dermatology Study Group (BVDSG), said: “The new chewable form of Apoquel provides owners with a means of controlling itch using a tablet that can be given like a treat or mixed with a meal, making it much easier for owners and more acceptable to their pet.
“In many cases, the chewable formulation will be the obvious first-line Apoquel for veterinarians to prescribe to control canine itching while the underlying cause of allergic dermatitis is investigated.”
Ceva Animal Health is launching Fiprospot, a new spot-on for dogs and cats.
Fiprospot contains fipronil, with its proven efficacy against fleas in dogs and cats and against ticks in dogs. The product is packaged in a novel dosing pipette which can be placed on its stand before gathering the dog or cat for their treatment. There are five pack sizes available for Fiprospot: one for cats and four for dogs, with either three or six pipettes per pack.
To find out more about Fiprospot and other products in Ceva's antiparasite range, telephone the customer support team on (01494) 781510 or contact your local Ceva territory manager.
Virbac Animal Health has launched CaniLeish, the first vaccine for canine leishmaniosis in the European Union.
Leishmaniosis is a vector-borne parasitic disease caused by infection with protozoa of the genus Leishmania (L infantum in Europe). Leishmaniosis is transmitted by the bite of infected sandflies. In south-western Europe 2.5 million dogs are believed to be infected1,2 with the parasite and the disease is spreading northwards,3 as more people travel with their dogs or import infected animals from endemic areas.4 So far preventative methods have been limited to reducing the habitat of sandflies, minimising the physical contact of dogs with sandflies and using insecticides on dogs (sprays, spot-ons, repellent-collars, etc).
According to Virbac, CaniLeish's ability to protect dogs was demonstrated in an experimental challenge study, where the benefit of vaccination was still evident after one year.5 In an extreme condition natural challenge trial lasting two years under environmental conditions rarely encountered in reality, 93% of dogs vaccinated with CaniLeish did not develop symptomatic leishmaniosis. CaniLeish provides a fourfold reduction in the risk of developing this fatal disease. 6 Its safety profile has been shown in laboratory testing and field trials.7 In addition, Virbac says it contains no whole parasites that could be virulent in any host.
David McGahie BVMS Bsc (VetSci) MRCVS, Medical Department Manager at Virbac SA, said: "The development of this vaccine is a key milestone in the battle against this challenging disease which is a major problem in many regions of the world. Although in the past it was considered a rather exotic disease here in the UK, the advent of the Pet Travel Scheme means it has become increasingly important as a problem for dogs which regularly travel abroad to endemic regions."
CaniLeish can be given to dogs as young as six months of age: the primary course consists of three injections given over six weeks. Dogs should be re-vaccinated annually, with a single dose administered one year after the third injection and annually thereafter.
References: